The mission of the Case CCC Tissue Resources Core Facility is to coordinate five services: tissue procurement, biorepository, tissue processing, histology, and immunohistochemistry (IHC). Tissue procurement prospectively collects, prepares, and distributes human tissue samples and associated deidentified data directly to investigators and/or to the biorepository, tissue processing, histology, and IHC components. Within these components, services such as tissue microarrays (TMAs), immunofluorescence, in situ hybridization, microscopy and digital imaging, and laser capture microdissection (LCM) are provided for both procured human tissue and animal research tissues transferred to the Core by investigators. The Core collaborates with researchers to assist them as needed in the IRB approval process, to advise them on sample availability, and to perform special tissue collection, dissection, and processing procedures. Malignant, pre-malignant benign, diseased, and normal tissues are obtained from surgical resections and autopsies. Normal adjacent tissue and tissues from different organ sites from the same donor are also available to researchers. All work is conducted in a manner that preserves sample integrity, protects donor identity, and facilitates the minimization of disruptions to surgical operating rooms and surgical pathology units during the collection process. The Tissue Resources Core is a critical resource for projects requiring human tissues for research and services that are not easily duplicated in other laboratories, such as automated IHC;or are significantly limited when accessed through a resource such as clinical pathology laboratories of area hospitals. Members from all the research programs use the services on a large scale. Access to clinical archived FFPE tissues has high impact on research projects, since large numbers of samples with clinical annotations and outcome data may be obtained within a short period of time. In continuation of its record of contributions to the advancement of science in past years, the Tissue Resources Core facilitates the research Case CCC members conduct. Services and materials provided by the Core have assisted research in gastrointestinal, breast, female genital, hematopoietic, lung, brain and prostate cancer. During the period 2006-2012 there were >74 publications from Case CCC members in journals such as J Pathol, Prostate, Oncogene, Clin Cancer Research, Neoplasia, Int J Cancer, Cancer Epidemiol Biomarkers, and Lung Cancer.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA043703-23
Application #
8484967
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2018-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
23
Fiscal Year
2013
Total Cost
$143,808
Indirect Cost
$52,643
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Liu, Xia; Taftaf, Rokana; Kawaguchi, Madoka et al. (2018) Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. Cancer Discov :
Belur Nagaraj, Anil; Joseph, Peronne; Kovalenko, Olga et al. (2018) Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. Gynecol Oncol 151:525-532
Li, Jiayang; Gresham, Kenneth S; Mamidi, Ranganath et al. (2018) Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy. Int J Cardiol 273:168-176
Enane, Francis O; Saunthararajah, Yogen; Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9:912
Lennon, Donald; Solchaga, Luis A; Somoza, Rodrigo A et al. (2018) Human and Rat Bone Marrow-Derived Mesenchymal Stem Cells Differ in Their Response to Fibroblast Growth Factor and Platelet-Derived Growth Factor. Tissue Eng Part A 24:1831-1843
Evans, Daniel R; Venkitachalam, Srividya; Revoredo, Leslie et al. (2018) Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer. Hum Mutat 39:1092-1101

Showing the most recent 10 out of 1227 publications